Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

News and Trends 7 Jun 2016

Zurich is not all about Money – here are 9 Biotechs proving it!

The biggest city in Switzerland, Zurich, is one of Europe’s top financial centers and home to the SIX Swiss Exchange (SWX). It’s also one of the most expensive cities in Europe to live in (as my Swiss colleague Claire could confirm). With so much money nearby, how does the local Biotech ecosystem looks like? The biggest Biotech/mid-size Pharma in […]

June 7, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 7 Jun 2016

Understand which transporters are involved in a drug’s absorption, distribution & excretion

How can you build the best case for a new drug application to the regulatory agencies? Preclinical studies are a crucial part in determining the pharmacokinetics of a drug – and more specifically how it is going to interact with drug transporters. So reaching out to the leading provider and consultant in this area (with strong […]

June 7, 2016 - 4 minutesmins - By Dani Bancroft

News and Trends 6 Jun 2016

‘Living’ Therapeutics in Boston attract major French Microbiome Money

Health for Life Capital, managed by Seventure Partners, has invested $8M (€7.15M) as part of a $50M financing round completed by Boston-based Vedanta Biosciences. This seems to be a great match between one of the most influential Microbiome investors and one of the most successful Microbiome biotechs. The basis for the financing is a live-bioproduct from […]

June 6, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 6 Jun 2016

Swiss-US Implant could make taking pills obsolete in Autoimmune Diseases

Numab and Intarcia have achieved key milestones in the development of therapeutic antibody fragments. This collaboration could span the next generation of implantable drug delivery tech for diabetes, obesity and autoimmune diseases. Based in Wädenswill (near Zurich), Numab is developing antibody-based therapeutics. With its ultra-high throughput technology, it can find rare molecules with big therapeutic potential that are […]

June 6, 2016 - 2 minutesmins - By Denise Neves Gameiro

car t cancer immunooncology biotech labiotech refresh georges rawadi

News and Trends 6 Jun 2016

CAR-T: “This is totally different from what everyone else is doing”

And on the topic of CAR-T, Joachim spoke to Georges Rawadi from the Belgium based biotech, Celyad. Having originally been built on research into a cell therapy for cardiology, Celyad started back in 2007. Now Rawadi explained it’s coming to the end of a cycle for the Cardiology programme. So naturally, they asked what next? Well – […]

June 6, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 4 Jun 2016

BioArt : Nurit Bar-Shai’s ‘Chemical Tweets’ and the Social Life of Bacteria

Nurit Bar-Shai is an artist and co-founder of bio-hacking lab Genspace. She is showing how bacteria communicate and socialize – and shaping it with sound. An Israeli-American multimedia artist, Nurit Bar-Shai composes video, live telematic installations and conducts experiments – working at the interface between art, science, and technology. She is also a co-founder and the Art and […]

June 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

News and Trends 3 Jun 2016

Biotech of the Week: High-quality genetic testing with Asper Biotech in Estonia

This week we decided we needed a geographical change and explore slightly different territories… The Baltic sea was a good solution, we thought, so that’s why we are leaving Paris to head up to Tartu, in Estonia, to visit Asper Biotech, our Biotech of the Week. City: Tartu (Estonia) Founded: 1999 Employees: 11 – 50 (as of […]

June 3, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 2 Jun 2016

RNA therapy starts first-of-a-kind trial to treat Liver Cancer

MiNA Therapeutics is launching the first saRNA human trial of its kind – OUTREACH for patients with severe liver cancer. MiNA Therapeutics is a London based RNA specialist, developing RNA activation therapeutics that restore normal function to patients’ cells with an initial focus on severe liver cancer. The study is the first-in-human trial of a small activating RNA […]

June 2, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 2 Jun 2016

First All-Cancer mRNA Vaccine that Works Published in Nature

Update (05/07/2017): BioNTech has published new results in Nature revealing a strong immune response in all 13 patients treated with its personalized mRNA cancer vaccine, strengthening its potential to become a universal cancer vaccine. Originally published on 02/06/2016 BioNTech and its academic partners have published in the well-known publication Nature, describing the first clinically applicable and systemic […]

June 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 2 Jun 2016

A ‘Skin Spray’ could cure Chronic Skin Wounds caused by Diabetes

Avita has initiated a trial in the UK to evaluate the potential of its ReGenerCell technology to treat diabetic foot ulcers, a skin wound that can be very hard to treat. With offices in the UK and originally from Australia, Avita Medical is developing products in tissue engineering and regenerative medicine. Its technology utilises the […]

June 2, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 1 Jun 2016

Novel Bionic Vision device gains approval for clinical trials in Renowned UK Hospital

Pixium Vision will be testing its new IRIS II bionic vision system in a clinical trial. The device can mimic eye function in people affected by Retinitis pigmentosa and Macular degeneration. Based in Paris (France), Pixium Vision is developing an alternative for people who have lost their sight – a bionic vision restoration system (VRS). One […]

June 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 1 Jun 2016

EMA approves Groundbreaking Gene Therapy for Super Rare ‘Bubble Baby’ Disease

GSK, Fondazione Telethon and Ospedale San Raffaele have announced that the EMA has approved Strimvelis for a super rare immunodeficiency disease in Children. Following 20 years of research at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Italy, this is the news patients have been waiting for. Strimvelis is the first ex vivo stem cell gene […]

June 1, 2016 - 3 minutesmins - By Dani Bancroft

ADVERTISEMENT